Abbott Plans R&D, Marketing Investments For i-STAT Following Acquisition
This article was originally published in The Gray Sheet
Executive Summary
i-STAT will be assured access to Abbott's brain natriuretic peptide (BNP) marker to develop a point-of-care myocardial infarction diagnostic if a proposed $392 mil. merger is approved by i-STAT shareholders
You may also be interested in...
Roche Diagnostics Inks Second ProBNP Test Development Deal
Syn X Pharma aims to bring its NT-proBNP Nexus Dx point-of-care test for the detection of congestive heart failure to the U.S. market by the second half of 2004
Abbott To Market I-Stat POC Blood Analyzer Worldwide Under Aug. 4 Alliance
Abbott is rounding out its hospital point-of-care testing portfolio and providing I-Stat with access to a worldwide network of direct sales representatives through a long-term sales, marketing and research alliance announced Aug. 4 at the American Association for Clinical Chemistry conference in Chicago.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.